ThyroSafe 65mg Review: The Best FDA-Approved KI for Families
FDA Verified — ANDA ApprovedIf your household includes children aged 3–12, ThyroSafe 65mg is the single most practical FDA-approved potassium iodide product available. It is the only FDA-approved KI tablet manufactured at the 65mg strength — which happens to be the exact dose recommended by the FDA and CDC for children 3–12 years old. No splitting. No guesswork. One tablet, one child dose.
Manufactured by Recipharm AB in Sweden and distributed in the U.S. primarily through MIRA Safety, ThyroSafe has earned a strong reputation among families, emergency preparedness communities, and institutional buyers across NATO partner nations.
| Manufacturer | Recipharm AB (Sweden) |
|---|---|
| U.S. Distributor | MIRA Safety |
| FDA Status | ANDA-Approved |
| NDC Number | 66983-350 / 50633-910 |
| Strength | 65mg potassium iodide per tablet |
| Count Options | 20, 40, 120, or 240 tablets |
| Form | Cross-scored white tablet |
| Shelf Life | 6–7 years (FDA-approved, extensions possible) |
| Price | ~$12–$15 (20 tablets) |
| Note | Contains lactose |
The Family Dosing Advantage
The cross-scoring on each ThyroSafe tablet allows it to be cleanly broken into four pieces — each quarter providing approximately 16.25mg. This means a single tablet can be divided to serve multiple pediatric age groups without the imprecision of trying to split a 130mg tablet into eighths for neonatal dosing.
For a family of four with two adults and two children aged 5 and 8, the dosing is straightforward: each adult takes 2 tablets (2 × 65mg = 130mg), each child takes 1 tablet (65mg). That's 6 tablets per day for the whole family. A single 20-tablet pack covers your family for over 3 days of protection.
New: ThyroSafe 130mg Variant
In 2025, ThyroSafe launched a new 130mg variant (ASIN B0FPG5TSJP) in a 240-tablet package with expiration dates extending to April 2035. This gives ThyroSafe buyers the option of a full-strength adult dose in a single tablet while maintaining the ThyroSafe quality standard. See our ThyroSafe 130mg review for details.
ThyroSafe vs iOSAT
The choice between ThyroSafe and iOSAT comes down to household composition. If your household is adults only and you want maximum shelf life (10 years), iOSAT wins. If you have children ages 3–12, ThyroSafe's 65mg dose eliminates the imprecision and hassle of tablet splitting. Read our detailed iOSAT vs ThyroSafe comparison for the full breakdown.
✓ Pros
- FDA ANDA-approved — verified potency and purity
- 65mg precisely matches the pediatric dose for children 3–12
- Cross-scored for quartering — supports infant dosing fractions
- More affordable per dose than iOSAT
- 20-tablet packs provide more total doses
- Now available in 130mg variant for adult convenience
- Amazon Transparency verified — anti-counterfeit protection
✕ Cons
- 6–7 year shelf life — shorter than iOSAT's 10 years
- Contains lactose — concern for lactose-sensitive individuals
- Adults need 2 tablets per dose (less convenient than single 130mg)
- Manufactured in Sweden — some prefer US-made products
$12–$15
Frequently Asked Questions
Yes. ThyroSafe is FDA ANDA-approved. You can verify this by searching NDC 66983-350 on the FDA's DailyMed database.
Adults need 2 tablets (2 × 65mg = 130mg) per dose. Children 3–12 need just 1 tablet (65mg).
Yes, ThyroSafe contains lactose as an inactive ingredient. If you have severe lactose intolerance or lactose allergy, consult your healthcare provider. The amount of lactose per tablet is small.
ThyroSafe has a manufacturer-guaranteed shelf life of 6–7 years. The FDA Shelf Life Extension Program may extend this further for properly stored tablets. The new 130mg variant has expiration dates extending to April 2035.